Working… Menu

To Compare Intravitreal Clindamycin & Dexamethasone With Classic Treatment of Toxoplasmic Retinochoroiditis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00372294
Recruitment Status : Unknown
Verified June 2008 by Shahid Beheshti University of Medical Sciences.
Recruitment status was:  Active, not recruiting
First Posted : September 6, 2006
Last Update Posted : July 30, 2008
Information provided by:
Shahid Beheshti University of Medical Sciences

Brief Summary:
Toxoplasmosis, an intra cellular parasite, is a very important cause of chorioretinitis. The goal of treatment is arresting multiplication of the parasite in its inflammatory active phase. In this study the investigators try to compare the efficacy of the classic regimen (Pyrimethamine-Sulfadiazine + Prednisolon) with intravitreal Clindamycin & Dexamethasone.

Condition or disease Intervention/treatment Phase
Chorioretinitis Drug: pyrimethamine-sulfadiazine + prednisolone Drug: Clindamycin+Dexamethasone Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Study Start Date : July 2005
Estimated Primary Completion Date : August 2008
Estimated Study Completion Date : November 2008

Arm Intervention/treatment
Active Comparator: 1
Classic regimen (Pyrimethamine-Sulfadiazine + Prednisolon)
Drug: pyrimethamine-sulfadiazine + prednisolone
Administration of pyrimethamine-sulfadiazine + prednisolone

Active Comparator: 2
Intravitreal Clindamycin & Dexamethasone
Drug: Clindamycin+Dexamethasone
Intravitreal injection of Clindamycin+Dexamethasone

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with Toxoplasmic chorioretinitis
  • Location of the lesion within zone I of the retina or a lesion greater than 2DD with 3+-4+ vitreous inflammation in zone II or III
  • No allergic history to the used drugs
  • No any other diseases

Exclusion Criteria:

  • Any allergic reaction to the used medications
  • One eyed patients
  • Partially treated patients

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00372294

Layout table for location information
Iran, Islamic Republic of
Ophthalmic Research Center
Tehran, Iran, Islamic Republic of, 16666
Sponsors and Collaborators
Shahid Beheshti University of Medical Sciences
Layout table for investigator information
Principal Investigator: Masoud Soheilian, MD Ophthalmic Research Center of Shaheed Beheshti Medical University

Layout table for additonal information Identifier: NCT00372294     History of Changes
Other Study ID Numbers: 8415
First Posted: September 6, 2006    Key Record Dates
Last Update Posted: July 30, 2008
Last Verified: June 2008
Keywords provided by Shahid Beheshti University of Medical Sciences:
Intravitreal Clindamycin
Dexamethasone in chorioretinitis
Additional relevant MeSH terms:
Layout table for MeSH terms
Retinal Diseases
Eye Diseases
Choroid Diseases
Uveal Diseases
Uveitis, Posterior
Clindamycin palmitate
Clindamycin phosphate
Dexamethasone acetate
Methylprednisolone Acetate
Methylprednisolone Hemisuccinate
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate
BB 1101
Anti-Inflammatory Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs